IOBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IO Biotech Inc (IOBT) is not a good buy for a beginner investor with a long-term strategy. The stock is experiencing significant price declines, has poor financial performance, and lacks positive catalysts. Analysts have downgraded the stock significantly, citing failed trials and capital constraints. There are no strong trading signals or recent influential purchases to support a buy decision.
The stock is in a bearish trend with MACD negatively expanding, RSI indicating oversold conditions at 10.328, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are far below the current price, suggesting further downside potential.
NULL identified. There are no recent news or significant positive developments for the company.
The company faces capital constraints, failed Phase 3 trials for its lead program, and FDA recommendations against regulatory filing. Analysts have downgraded the stock with significantly reduced price targets.
In Q3 2025, the company reported zero revenue growth, a net income drop of -65.11% YoY to -$8.38M, and an EPS decline of -63.89% YoY to -0.13. Gross margin remains at 0%.
Analysts have downgraded the stock from Overweight to Neutral and Underweight, with price targets reduced from $3 to as low as $0.36 and $0.50. The downgrades reflect failed trials, capital constraints, and uncertainty around strategic alternatives.
